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According to the Delphi study, about 24 million people suffered from
dementia in 2001 worldwide and this ﬁgure was estimated to double in
2020 and quadruple in 2040 [1]. Alzheimer's disease (AD) is the most
common form of dementia and is characterized by cognitive andmemo-
ry decline, speech loss, personality changes and is one of themajor cause
of admission to nursing homes [2,3]. From an epidemiologic point of
view, the incidence of AD was shown to increase with age and doubled
every 5 years after 65 years of age with 1275 new cases/100,000 per-
sons/year [3]. The prevalence of AD was calculated as about 1% in sub-
jects aged 60–64 but increases up to 33% in people aged 85 or older, in
theWestern hemisphere [4]. However, the annual incidence worldwide
ranges from 1% to 7% at the ages of 70 and 85, respectively [5]. Sporadic
AD is the more common form of the disease, accounting for 90% of all
cases, whereas only 1% accounts for the familial form [2]. Although it
was not deﬁnitely proven, most of the sporadic AD is associated with
the ε4 allele of the apolipoprotein E (APOE), a plasma protein implicated
in the transport of cholesterol which binds amyloid-β-peptide (Aβ),
whereas familial AD is an autosomal dominant disorder, whose early
onset was associated with mutations in speciﬁc genes such as amyloid-β
precursor protein (APP), presenilin 1 and presenilin 2 [2,6]. Despite the
huge amount of data derived from preclinical and clinical studies aboutthe pathogenesis of AD, a limited number of drugs were developed
over the last years [7]. A growing interest was focused on dietary antiox-
idants contained in many foods due to their natural origin and the quite
good safety proﬁle [8–10]. However, although promising early evidence
of therapeutic beneﬁt, mainly provided by preclinical experimental ﬁnd-
ings, clinical studies demonstrated the relative inability of dietary antiox-
idants to delay the onset and progression of AD as well as to improve
cognitive function and the activities of daily living.
The aim of this paper is to provide an overview of themain pharma-
cologic features of the more common dietary antioxidants proposed to
have therapeutic activity in AD, such as curcumin (which belongs to
the polyphenol family),Ginkgo biloba extract (which containsﬂavonoids
and terpenes) and carnitines. In addition, themain outcomes reached by
clinical studies designed to demonstrate the effects of dietary antioxi-
dants in AD patients will be analyzed. Finally, the pros and cons of the
use of curcumin, Ginkgo biloba and acetyl-L-carnitine (ALC) in AD pa-
tients will be outlined.
2. The rationale for the use of antioxidants in AD
Amain role in AD pathogenesis is played by amyloid-β-peptide (Aβ)
and hyperphosphorylated tau protein [3,7,11]. Amyloid-β-peptide is
formed by the secretase-mediated cleavage of APP. β-secretase cleaves
APP at the N-terminus, generating an extracellular soluble fragment
(sAPPβ) and leaving an intramembrane fragment called C99 [3,12].
This latter is cleaved at the C-terminus by the γ-secretase and Aβ is re-
leased [3,12]. Once formed, Aβ aggregates as oligomers and ﬁbrils,
which form the central core of senile plaques (SP) [3,7,13]. Many
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aggregates [3,14,15]. β-amyloid peptide oligomers isolated from the
brain of AD subjects and administered to mice signiﬁcantly impaired
synaptic function and disrupted memory of a learned behavior [14].
On the other hand, insoluble Aβ plaques from AD patients became
toxic for mice if the aggregates were solubilized to release lowmolecu-
lar weight oligomers [14]. The evidence that Aβ oligomers are more
toxic than plaques provides a plausible explanation of the reason why
drugs targeted to facilitate the disgregation of Aβ ﬁbrils into oligomers,
e.g. bapineuzumab and solanezumab, failed to improve cognitive func-
tion in AD patients [12,16]. Amyloid-β-peptide exerts its neurotoxic ef-
fects through several mechanisms: (a) generation of superoxide anion
and nitric oxide through the activation of NADPH oxidase [17] and in-
ducible nitric oxide synthase (iNOS) [3,15,18], respectively, which
react with each other and form peroxynitrite (ONOO−); (b) mitochon-
drial impairment secondary to the inhibition of key enzymes involved
in the respiratory chain and Krebs-cycle [3]; (c) stimulation of the iono-
tropic glutamate receptor NMDA and increase of Ca2+ overload thus
leading to excitotoxic cell death [3]. Both ROS and ONOO− oxidize
and/or nitrate proteins and lipids thus contributing to cell death
[13,19]. The free radical-induced damage and opening of mitochondrial
membrane transition pores, causes cytochrome c release, caspase-3 ac-
tivation and apoptotic cell death [3,20]. On the other hand, Aβ promotes
the hyperphosphorylation of tau, a microtubule-associated structural
protein, by activating multiple kinases, such as GSK-3β and DYRK1A
[21]. Hyperphosphorylated tau aggregates and forms neuroﬁbrillary
tangles (NFTs) [3]. Hyperphosphorylated tau inhibits mitochondrial
complex I and synergizes with Aβ to damage mitochondria [3]. As a
consequence of increased oxidative/nitrosative stress and the opening
of mitochondrial membrane transition pores leading to cytochrome c
release and caspase-3 activation, apoptotic cell death takes place [3,20].
In this frame, the use of polyphenols and carnitine/ALC may be
useful since they enhance both the cell stress response and improve
mitochondrial respiration thus allowing the neuron to counteract
free radical-induced damage and produce the ATP necessary to main-
tain the normal membrane potential [8–10].
2.1. Curcumin
Curcumin (1,7-bis[4-hydroxy 3-methoxy phenyl]-1,6-heptadiene-
3,5-dione, Fig. 1) is a polyphenol extracted from the rhizome of Curcuma
longa Linn (family Zingiberaceae) and it is commonly used in the Asian
continent, in particular India, as a spice to make food colored and ﬂa-
vored. Furthermore, curcumin is considered by the traditional Indian
medicine as a therapeutic effective on several disorders including an-
orexia, coryza, cough, hepatic diseases and sinusitis [22,23].
Curcumin is quite stable at acidic pH and almost 40–80% of this com-
pound is found unaltered in the gastrointestinal tract upon oral admin-
istration [22]. However, curcumin undergoes a marked ﬁrst-pass effect
which limits its systemic bioavailability (~ 60%) as demonstrated in
humans and rodents [24–26]. In order to increase its bioavailability,
the co-administration of curcumin with piperine [27] or its complexa-
tion with phospholipids or other vehicles to form lipophilic adductsFig. 1. The chemical structure of curcumin.[28–32] was proposed. The rationale for the co-administrationwith pip-
erine is that this compound inhibits both hepatic and intestinal glucuro-
nidating enzymes as well as the efﬂux pump P-glycoprotein thus
increasing the amount of free-curcumin [27,33]. In humans treated
with 2 g curcumin plus 20 mg piperine the increase in curcumin bio-
availability was about 200% [27]. The complexation with phospholipids
or solid lipid nanoparticles (SLN) increased curcumin bioavailability of
5- and 39-fold factors, respectively [28–30]. The formation of curcumin
adducts with lipophilic vehicles seems to be a better strategy to increase
its bioavailability than the co-administration with piperine. Shaikh et al.
found that the complexation with polylactide-co-glycolide (PLGA) im-
proved curcumin oral bioavailability of a 9-fold factor compared to
that reachedwith the co-administration of the polyphenolwith piperine
[32]. Preclinical studies showed as the administration of 100 mg/kg of
curcumin per os to the rat allows the polyphenol to reach peak plasma
concentration (Cmax) values around 90 ng/ml (~0.24 μM) with a Tmax
(time to reach Cmax) of 0.5 h which increase at 121.2 ng/ml (~0.33 μM)
and Tmax 0.75 h in the presence of 10 mg/kg piperine [32]. The Cmax in-
creases alsowhen curcumin is complexedwith liposoluble vehicles. Rats
treated with 50 mg/kg curcumin-SLN complex have a Tmax of 0.5 h and
Cmax of 14.29 μg/ml (~38 μM), this latter being about 50-times higher
than that reached in rats exposed to control curcumin formulation solu-
bilized with Tween80 [30]. Similar results were obtained in rats treated
with 100 mg/kg curcumin-PLGA per os in which the Cmax approaches
260 ng/ml (~0.71 μM), about 3-times higher than that found in rats as-
suming standard curcumin suspension [32]. However, the Tmax value
for curcumin-PLGA was 2 h [32]. Lower Cmax values of curcumin were
found in humans. The oral administration of 450–3600 mg of curcu-
min/day for 1 week to patients affected by colorectal cancer produced
a plasma concentration of ~3 nM [34]. Plasma levels up to 160 nM
reached after 2–5 h from the administration, were obtained in healthy
volunteers exposed to oral curcumin at supra-therapeutic doses (10–
12 g/day) [35]. These low plasma concentrations of curcumin did not
depend on the acute regimen of treatment. Indeed, chronic administra-
tion of curcumin (1–4 g/day for 6 months per os) initiated plasma con-
centrations in the range 60–270 nM [36]. In the rat, the volume of
distribution of curcumin is around 190 l thus suggesting that this poly-
phenol may accumulate in many organs including colorectal tissue and
liver and it decreaseswhen the polyphenol is complexedwith phospho-
lipids or SLN [24,28,30]. Studies in rodents and humans demonstrated
that, after oral administration, curcumin undergoes phase I reactions
and is reduced into dihydrocurcumin (DHC), tetrahydrocurcumin
(THC), hexahydrocurcumin, octahydrocurcumin and hexahydrocurcu-
minol as well as phase II reactions originating curcumin glucuronide
and curcumin sulfate [22,37,38]. These metabolic changes were shown
to occur not only in the liver, themain organ deputed to biotransforma-
tion, but also in the intestinal tract [22,38]. Interestingly, the metabo-
lism of curcumin generates products such as THC which retains
antiinﬂammatory activity comparable to that of the parental compound
[22,38]. It is important to recall the interaction of curcumin with drug-
metabolizing enzymes and the possible repercussions on health. Curcu-
min and its derivatives inhibit the activity of several isoforms of drug
metabolizing enzymes such as cytochrome P450 (CYP), including
CYP3A4, glutathione-S-transferase and UDP-glucuronosyltransferase
[39–42] and this effect may be responsible for an undesired increase
in plasma concentrations of drugs metabolized through these enzymes
such as digoxin, acetaminophen and morphine [43]. Furthermore, even
piperine, which has been used in combination with curcumin to in-
crease its bioavailability, has been shown to be a non-competitive inhib-
itor of CYP3A4 [40]. The inhibition by curcumin, alone or in combination
with piperine, of CYP3A4 is potentially harmful, in particular in the case
of prolonged exposure to these substances. In fact, it was shown that
CYP3A4 inhibitorsmay alter themetabolismof several drugs commonly
used in old people, e.g. amiodarone and quinidine, thus increasing the
risk to develop life-threatening ventricular arrhythmias such as torsades
de pointes [43,44]. Donepezil and galantamine, commonly used in AD
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this reason, the concomitant administration of donepezil and galanta-
mine with curcumin alone or plus piperine could increase the half-life
of these drugs and exacerbate their side effects such as fatigue, nausea,
emesis andmuscle cramps, dizziness and sinusitis [45,46]. In the rat, cur-
cumin is mainly excreted into the bile and then eliminated by the feces,
only a little amount is eliminated by the urine [25,26] and the elimina-
tion half-life is ~1.5 h [28]. The urinary elimination of curcumin and its
metabolites seems to be increased if curcumin is administered at large
doses (for example 3.6 g/day for up to 4 months) [24,47]. With regard
to the safety proﬁle, curcumin was shown to be carcinogenic and to
cause DNA damage and chromosomal alteration in mammalian cell
lines at concentrations close to those reported to exert beneﬁcial effects
[48]. In addition, curcumin behaved as an iron chelator and induced iron-
deﬁcient anemia in mice fed with diets poor in iron [48]. Studies in ro-
dents and primates have shown that the spice at doses up to 3.5 g/kg
body weight administered for up to 3 months were well tolerated by
the animals [24]. However, patients affected by advanced colorectal can-
cer treated with curcumin 3.6 g/day developed diarrhea whereas the
dose of 0.9 g/day was associated with nausea, which resolved spontane-
ously. In the same patients, blood test abnormalities correlatedwith cur-
cumin administration were a rise in serum alkaline phosphatase and
lactate dehydrogenase [24,47].
The early evidence of a protective role of curcumin in AD derived
from epidemiological studies. Ganguli and colleagues demonstrated
that Indian population,whohas a curcumin-enriched diet, has a reduced
prevalence of AD compared to United States [49]. Following this initial
observation, several preclinical studies showed the cytoprotective ef-
fects of curcumin (Table 1). In vitro studies showed that curcumin and
derivatives (0.2–27 μM) protected neuron-like PC12 rat cells and nor-
mal human umbilical vein endothelial (HUVEC) fromβ-amyloid toxicity
and, interestingly, the polyphenol displayed a neuroprotective effect
greater than a well known antioxidant such asα-tocopherol [50]. In ad-
dition, curcuminoids were shown to restore synaptic plasticity, evaluat-
ed as long term potentiation, signiﬁcantly damaged by Aβ treatment in
rat hippocampal slices [51]. Curcumin exerts indirect effects by either
inhibiting pro-inﬂammatory transcription factors (NFkB and activator
protein-1) and enzymes (cyclooxygenase, lipoxygenase, inducible nitric
oxide synthase etc.) [52] or stimulating detoxifying enzymes such asTable 1
Some of the main intracellular targets involved in the pharmacological effects of
curcumin.
Curcumin
Target(s) Experimental model(s) Pharmacological effect Reference(s)
NFkB,
AP-1
hML-1a cells Inhibition of inﬂammatory
response
[118,119]
Rat liver
iNOS hKBM-5 cells Inhibition of inﬂammatory
response
[119,120]
Rat liver
Bcl-2,
Bcl-xL
hKBM-5 cells Activation of apoptotic
cascade
[120]
COX-2 hKBM-5 cells Inhibition of inﬂammatory
response
[119,120]
Rat liver
GST Rat liver Inhibition of carcinogenesis [53]
HO-1/BVR Rat neurons Enhancement of the cell
stress response
[121–123]
Rat astrocytes
pLLC-PK1 cell line
rNRK-52E cell line
Bovine endothelial
cells
IL-1β Tg2576 mice Inhibition of inﬂammation [57]
APP Tg2576 mice Reduction of senile plaques [57,58]
APPswe/PS1dE9
mouse
AP-1, activator protein-1; APP, amyloid precursor protein; Bcl-2, B-cell lymphoma-2;
Bcl-xL, B-cell lymphoma-extra large; COX-2, inducible cyclooxygenase; GST,
glutathione-S-transferase; h, human; IL-1β, interleukin-1β; iNOS, inducible nitric
oxide synthase; HO-1/BVR, heme oxygenase-1/biliverdin reductase system; NF-kB, nu-
clear factor kB; p, porcine; r, rat.glutathione-S-transferase [53] (Fig. 2 and Table 1). Furthermore, curcu-
min potentiated the cell stress response through the activation of the
heme oxygenase-1/biliverdin reductase (HO-1/BVR) system as well as
other members of the heat shock protein family in several rodent and
human cell lines, including rat neurons and astrocytes [54] (Fig. 2). In
particular, the ability of curcumin and other natural compounds, such
as Ginkgo biloba (see below), to induce the cell stress response is quite
interesting and put these natural compounds in the “hormetin arena”.
In other words, a mild stressful condition elicited by the hormetins acti-
vates antioxidant systems, such as the HO-1/BVR pathway which, in
turn, exerts it cytoprotective effect by degrading heme, which is toxic
if produced in excess, and generating the powerful free radical scaven-
ger bilirubin [54–56].
By using an Alzheimer transgenic APPSw mouse model (Tg2576),
Lim and colleagues showed that dietary curcumin (160–5000 ppm)
suppressed inﬂammation and oxidative damage in the brain of
these mice [57]. Garcia-Alloza et al. in transgenic APPswe/PS1dE9
mice demonstrated that curcumin 7.5 mg/kg/day intravenously for
7 days, crosses the blood–brain-barrier, binds to β-amyloid deposits
in the brain and accelerates their rate of clearance [58]. Although
these are promising preclinical ﬁndings, the beneﬁcial effect of curcu-
min in AD patients was not proved so far. Curcumin 1–4 g/day for
6 months did not reduce peripheral biomarkers of inﬂammation,
such as serum Aβ and isoprostanes, in AD patients; more importantly,
curcumin did not ameliorate cognitive performance in these patients
[36]. Since curcumin was hypothesized to have a protective role in
cardiovascular diseases due to its ability to reduce cholesterolemia,
the same AD patients were monitored also for the plasma lipid pro-
ﬁle. The results clearly demonstrated that curcumin did not have
any signiﬁcant beneﬁcial effect on plasma triglycerides or total, LDL
and HDL cholesterol over 1 or 6 months, rather a slight increase in
cholesterol plasma levels was detected in AD patients when the
absorbed dose of curcumin was taken into consideration [59].
2.2. Ginkgo biloba
Ginkgo biloba, a plant whose places of origin are the remote moun-
tainous valleys of Eastern China, is considered a “living fossil”. Although
Ginkgo biloba's extracts contain several active compounds, including ﬂa-
vonoids, terpenes, organic acids and polyphenols, the most important
ones are ﬂavonol-glycosides (quercetin, kaempferol and isorhamnetin
derivatives) and terpene-lactones (Fig. 3). These latter are further divid-
ed into diterpenes (ginkgolides) and sesquiterpenes (bilobalide) [60,61].
Flavonol-glycosides and terpene-lactones are endowedwithmany phar-
macological activities such as the antagonism on platelet activating fac-
tor and neuroprotection [60–62].
Ginkgo biloba extract iswell absorbed by oral route: the bioavailability
for ﬂavonol-glycosides is N60%, for ginkgolides N98% and for bilobalide
~70% [63]. Both ﬂavonol-glycosides and terpene-lactones are mainly
adsorbed in the small intestine, even if the possibility of a gastric absorp-
tion of ginkgolide B could not be excluded [63–65]. Preclinical studies
showed that in rats treated with Ginkgo biloba extract containing 20.3,
14.7 and 3.2 mg/kg of quercetin, kaempferol and isorhamnetin, respec-
tively, the Cmax values of each compoundwere 179.21 ng/ml (quercetin),
180.23 ng/ml (kaempferol) and 195.96 ng/ml (isorhamnetin) and the
Tmax were 1.21 h, 6.32 h and 7.21 h, respectively [62]. Similar results
were obtained in rats treated orally with Egb 761® (a Ginkgo biloba ex-
tract containing 24% ﬂavonol-glycosides and 6% terpenes) at the dose of
600 mg/kg [66]. Interestingly, repeated administration of 600 mg/kg
Egb 761® for 8 days led to 4.5-fold, 11.5-fold and 10-fold increases in
plasma concentration of quercetin, kaempferol and isorhamnetin, respec-
tively [66].With regard to terpene lactones, data in humans are available.
After the administration of 160 mg of Ginkgoselect® (a product with the
same composition of Egb 761®) to healthy male volunteers, Cmax values
of ~42 ng/ml, 5.6 ng/ml and 37.6 ng/ml for ginkgolide A, B and bilobalide,
respectively, were reached after 2 h [67]. In the same subjects, the half-
Fig. 2. The main intracellular pathways involved in the neuroprotective effects of curcumin, Ginkgo biloba and acetyl-L-carnitine. For further information see text and Tables 1–3.
Arrows, stimulation; dotted lines, inhibition.
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values are different from those found by Kleijnen and Knipschild who
calculated elimination half-lives of 4–6 h and3 h for ginkgolides and bilo-
balide, respectively [63]. Terpene-lactones were shown to cross the rat
blood–brain barrier, and the concentrations in brain tissue were found
to be 55 ng/g, 40 ng/g and 98 ng/g for ginkgolide A, ginkgolide B and
bilobalide, respectively [68]. Similarly to curcumin, a phospholipidic com-
plex of ﬂavonol-glycosides and terpenes (Ginkgoselect® Phytosome®)
was prepared to improve bioavailability. In rats treated orally with a
phospholipidic formulation of Ginkgo biloba extract, equivalent to doses
of 20.3, 14.7 and 3.2 mg/kg of quercetin, kaempferol and isorhamnetin,Fig. 3. The chemical structures of the maithe Cmax of each compound increased 4.04, 1.79 and 3.44 times, respec-
tively, compared to Ginkgo biloba extract [62]. In human subjects treated
with 160 mg of Ginkgoselect® Phytosome®, Cmax values of ~108 ng/ml,
13.4 ng/ml and60.3 ng/ml for ginkgolideA, B andbilobalide, respectively,
where reached after 3–4 h from the administration [67]. Ginkgolides A
and B are mainly excreted unchanged in the urine (70% and 50%, respec-
tively), whereas for bilobalide this ﬁgure is about 30% [63]. The adminis-
tration of Ginkgo biloba extracts is quite safe. Only mild adverse effects
were recorded including mild gastrointestinal complaints, headache
and allergic symptoms [63]. However, important interactions between
Ginkgo biloba and commondrugs should be underlined. Due to the abilityn Ginkgo biloba's active components.
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reduced omeprazole plasma concentration and this effect was marked
in individuals sharing the status of poor metabolizers [69]. The induction
of CYP2C19 by Ginkgo biloba was shown to increase metabolism and
reduce plasma concentrations of antiepileptic drugs such as valproic
acid and phenytoin, thus increasing the risk of fatal seizures [70]. Finally,
ginkgo's ﬂavonol-glycosides caused coma in a 80-years individual with
AD treated with trazodone [71]. This severe side effect was hypothe-
sized to be due to a marked stimulation of CYP3A4 activity which in-
creased the transformation of trazodone into the active metabolite
1-(mchlorophenyl) piperazine which, in turn, increased GABAergic
activity in the brain and precipitated coma [71].
Several preclinical studies in rodents put forth the neuroprotective
role of Ginkgo biloba, mainly due to its ability to prevent free radical-
induced damage, increase the intracellular levels of antioxidant en-
zymes and restore calcium homeostasis [72–75] (Fig. 2 and Table 2).
Relevant to this paper are the several ﬁndings related to the neuropro-
tective effect of Ginkgo biloba in both in vivo and in vitromodels of AD.
EGb 761 failed to modify α- and β-secretase expressions and activities
in rat hippocampus and cortex as well as in the Neuro-2A cell line and
in the Tg2576 transgenic mouse [76,77], but inhibited the formation of
Aβ ﬁbrils in a neuroblastoma cell line overexpressing an AD-associated
double mutation [78]. Furthermore, EGb 761 (10–100 μg/ml) dose
dependently counteracted Aβ-induced toxicity in rat hippocampal pri-
mary cultured cells [79]. This neuroprotective effect was demonstrated
when rat hippocampal cells were treated with EGb 761 before and con-
comitantly with Aβ [79]. The antioxidant effect of EGb 761 seemed to be
attributable to the ﬂavonoid fraction rather than the terpene-lactones
fraction [79]. This last ﬁnding was also conﬁrmed by the evidence that
single ﬂavonol-glycosides as quercetin are neuroprotective against
Aβ-induced neuronal damage. As shown by Ansari et al., quercetin
counteracted Aβ-induced protein and lipid oxidation and attenuated
apoptosis in rat cortical neuronal cultures [80]. Since ROS and RNS are
mainly involved in Aβ-induced neurotoxicity, the efﬁcacy of Ginkgo
biloba was also speciﬁcally tested against these free radicals. EGb 761
(10–100 μg/ml) improved survival and inhibited ROS and RNS accumu-
lation in rat primary mixed hippocampal cell cultures exposed to
sodium nitroprusside [81] or in neuroblastoma cell line overexpressing
an AD-associated double mutation treated with hydrogen peroxide
[82]. These Authors conﬁrmed the selective neuroprotective effect of
the ﬂavonol fraction and the relative inefﬁcacy of ginkgolides and bilo-
balides [81]. Among the mechanisms through which EGb 761 exerts its
neuroprotective effects, the inhibition of the apoptotic cascade through
the block of caspase-3 activation [78] and the phosphorylation of the
pro-survival transcription factor CREB is worthy of mention [83]Table 2
Some of the main intracellular targets involved in the pharmacological effects of Ginkgo
biloba.
Ginkgo biloba
Target(s) Experimental model(s) Pharmacological
effect
Reference(s)
Catalase, SOD Rat brain Neuroprotection [72]
Voltage-gated
calcium channels
rCGN Restoration of
calcium homeostasis
[75]
Caspase-3 rCGN Inibition of the
apoptosis cascade
[75,78]
N2a/N2aAPP695
cell lines
Aβ N2a/N2aAPP695
cell lines
Inhibition of Aβ
aggregation
[78,83]
TgAPP/PS1 mouse
CREB TgAPP/PS1 mouse Stimulation of
neurogenesis
[83]
HO-1/BVR Mouse I/R injury Enhancement of the
cell stress response
[84,85]
Aβ, amyloid-β-peptide; CGN, cerebellar granule neurons; CREB, cAMP response element-
binding; HO-1/BVR, heme oxygenase-1/biliverdin reductase system; I/R, ischemia/
reperfusion; r, rat; SOD, superoxide dismutase.(Fig. 2). Similarly to curcumin, even Ginkgo biloba exerted neuroprotec-
tion through the activation of the HO-1/BVR axis in a mouse model of
ischemia/reperfusion brain injury [84,85] (Fig. 2).
Although these are promising preclinical evidence, the efﬁcacy of
Ginkgo bilobawas not conﬁrmed in AD patients. As a matter of fact, ear-
lier clinical trials demonstrated a slight improvement in cognitive func-
tions in individuals suffering from mild-to-moderate or moderate-to-
severe AD and treated with EGb 761 120–240 mg/day for short (12–
24 weeks) or long time (up to 52 weeks) [86–90]. On the other hand,
other clinical trials were not able to conﬁrm the efﬁcacy of EGb 761
(160–240 mg/day for 24 weeks) to ameliorate cognitive function in
mild-to-moderate AD patients, and the effect of Ginkgo biloba extract
was found comparable to placebo [91–93]. The inefﬁcacy of Ginkgo
biloba as a therapeutics in AD patients was conﬁrmed by two larger clin-
ical trial which evaluated the ability of this herbal product to prevent AD
in elderly subjects with normal cognitive function and in individuals
with mild cognitive impairment (MCI) [94,95]. The follow-up of this
trial was 6.1 years. The results of this study showed that Ginkgo biloba
extract, 120 mg twice a day, did not reduce the incidence of AD in
both healthy individuals and those suffering fromMCI [94,95]. A system-
atic review and meta-analysis conﬁrmed that the neuroprotective
effects of Ginkgo biloba are moderate, but their clinical relevance is difﬁ-
cult to evaluate [96].
2.3. L-Carnitine and derivatives
L-carnitine (LC, Fig. 4) is a natural compound and plays an impor-
tant function in mitochondrion biologic function since it facilitates
the transport of fatty acids to this organelle. Dietary LC derives from
the intake of red meats, but the endogenous synthesis of LC from the
amino acids lysine and methionine has been also documented [97].
The dietary intake of LC in humans is in the range 1–15 μmol/kg body
weight/day, whereas the rate of biosynthesis is about 1–2 μmol/kg
body weight/day [98]. Dietary LC is well absorbed by the gastrointesti-
nal tract by simple or carrier-mediated diffusion and its bioavailability isFig. 4. The chemical structures of L-carnitine and its derivatives.
Table 3
Some of the main intracellular targets involved in the pharmacological effects of acetyl-
L-carnitine.
Acetyl-L-carnitine
Target(s) Experimental model(s) Pharmacological effect(s) Reference(s)
Mitochondria Rat brain Improvement of synaptic
plasticity
[105,106]
Rat heart Stimulation of energy
metabolism
PKC Rat brain Amelioration of cognitive
function
[108]
NMDA
receptors
Rat brain Amelioration of cognitive
function
[111]
NGF Rat brain Amelioration of cognitive
function
[109,110]
HO-1/BVR
Hsp70
Rat brain Enhancement of the cell
stress response
[112,113]
HO-1/BVR, heme oxygenase-1/biliverdin reductase system; NMDA, N-methyl-D-
aspartate; NGF, nerve growth factor; PKC, protein kinase C.
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in the range 5–18% [97,98]. This paradoxical effect can be explained
considering that the absorption of LC decreases as the intake of LC in-
creases, this is to maintain the concentration of LC constant [97,98].
When administered at doses 30–100 mg/kg by oral route to humans,
the Cmax of L-carnitine is 27–91 μMwith Tmax 3 h, and the plasma con-
centration returns to the baseline within 24 h [98,99]. L-carnitine un-
dergoes extensive metabolism in rodents and human intestine thus
forming esteriﬁed compounds such as ALC and propionyl-L-carnitine
(PLC) (Fig. 4) which are endowed with biological activity per se. Inter-
estingly, ALC diffuses acrossmembranesmuch better than LC and its ef-
ﬂux in the systemic circulation has been calculated to be 4-times greater
than that of LC [98,100]. In healthy male volunteers treated with PLC
1–8 g as a single dose by intravenous infusion over 2 h, Cmax values of
9.4–16.4 nmol/ml and 143–1049 nmol/ml were reached for ALC and
PLC, respectively [101]. In the same study, the Tmax values for both
ALC and PLC were 2.4–3.1 h and 1.9–2.1 h, respectively [101]. Data
from AD patients showed that after supplementation with pharmaco-
logical doses of ALC (2 g/day) for 55 days, its plasma concentrations in-
creased from 7.2 to 10.3 μM[98]. Neither LC nor ALC nor PLC is bound to
plasma proteins [97,101]. The volume of distribution (Vd) of LC differs
considering the dietary or exogenous source being approximately
3000 l and 20–50 l, respectively [97]. This great difference in the volume
of distribution between dietary and supplemental LC depends on the
different degree of absorption, slow accumulation in tissues such as
the muscle and rate of kidney elimination (see below), and therefore
these numbers should be considered purely indicative [97]. Similarly,
PLC (1 g, single dose intravenously) has a Vd in the range 17.4–18.3 l
[101]. The elimination half-life for LC, ALC and PLC ranged 3–12 h, 4 h
and 1 h, respectively [97,101,102]. It is interesting to underlie that LC,
ALC and PLC are able to cross blood–brain-barrier [103]; Parnetti et al.
also showed as AD patients treated with ALC i.v. or p.o. for 10–60 days
have an increased concentration of ALC in the cerebrospinal ﬂuid up
to 3.55 nmol/ml [104]. Of note and according to aforementioned data,
the renal clearance of LC which is about 1–3 ml/min suggesting an
extensive rate of tubular reabsorption, signiﬁcantly increases at values
close to the creatinine clearancewith the increase in LC plasma concen-
trations indicating that tubular reabsorption approaches full saturation
[97]. This last ﬁnding is very important and concurs to explain how
exogenous LC is almost completely excreted during the ﬁrst 12 h after
administrationwhereas dietary LC is reabsorbed [97]. Due to its elimina-
tion mainly through the kidney, LC and should be administered very
carefully to patients affected by renal impairment. The basal renal-
excretory clearance of PLC, which is about 0.33 l/h, increases from
1.98 l/h to 5.55 l/h at doses of 1 g and 8 g, respectively, thus suggesting
an extensive tubular reabsorption [101].
Acetyl-L-carnitine was shown to exert beneﬁcial effects in prevent-
ing the loss of brain function which typically occurs during aging and
neurodegenerative disorders (Table 3). Preclinical and clinical studies
demonstrated that themainmechanismof action of ALC is the improve-
ment of mitochondrial respiration which allows the neuron to produce
ATP necessary to maintain the normal membrane potential [105–107]
(Fig. 2). In themeantime, ALC was shown to be neuroprotective by reg-
ulating other intracellular pathways, such as PKC, in the rat [107,108].
Interestingly, ALC counteracted the loss of NMDA receptors in rat neu-
ronal membrane and increased the production of neurotrophins, two
effects strictly related to synaptic plasticity [107,109–111] (Fig. 2).
With regard to the pathogenesis of AD, ALC reduces Aβ toxicity in rat
primary cortical neuronal cultures by increasing the cell stress response
through the activation of the heat shock proteins HO-1 and Hsp70 ex-
pression [112] (Fig. 2). Through the modulation of the heat shock pro-
tein family, ALC prevented age-related changes in mitochondrial
respiration and decrease oxidative stress biomarkers in senescent rat
brain [113]. Accordingly, ALC treatment increased life-span, improved
cognitive behavior in aged rats and guaranteed long-term memory per-
formance [107]. As a whole, these pre-clinical studies suggested thatALC treatment could be beneﬁcial for the treatment of age-related dis-
eases and the potential use in humans was explored. Patients affected
by AD and treated with ALC at doses ranging from 1 to 2 g/day for 6–
12 months, had an improved performance on several cognitive tests
such as word recognition, name learning and world list recall with
respect to placebo-treated patients, but none of these effects was signiﬁ-
cant [107,114]. In two clinical studies, ALC 3 g/day for 1 year signiﬁcantly
reduced cognitive decline only in early-onset AD patients [115,116], but
this evidence was not conﬁrmed in a later ad hoc designed study [117].
3. Conclusions
On the basis of preclinical and clinical evidence, the role of curcumin,
Ginkgo biloba and ALC in the therapy of AD is still under debate. Impor-
tant pharmacokinetic limitations, such as the poor biovailability and
harmful interactions with drug metabolizing enzymes, need to be care-
fully considered in case of curcumin and Ginkgo biloba administration.
Conversely, despite favorable pharmacokinetics (e.g. the ability to cross
blood–brain barrier) the lack of therapeutic effect of ALC in AD patients
seems to be related to its pharmacodynamics. In this frame, the develop-
ment of new drug-delivery systems which improve systemic bioavail-
ability and brain penetrance and allow the administration of natural
substances at low doses has to be considered a promising strategy.
This approach could also minimize the risk for adverse effects related
to unwanted ﬂuctuations in nutraceutical plasma concentrations. It is
an ambitious goal, however, and one that will require close, active col-
laboration by pharmacologists, chemists, and clinicians.
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